Drug Discovery Stories: From Bench to Bedside
Editat de Bin Yu, Peng Zhanen Limba Engleză Paperback – 18 oct 2024
The field of drug discovery and development has experienced rapid evolution, with numerous new drugs receiving approval each year. While several books have been published on this subject, there is a pressing need for a new book series that accurately reflects the current advancements in drug discovery. This book aims to not only cater to the drug discovery community but also engage other communities involved in chemical biology, synthetic chemistry, and pharmacology.
- Analyzes the drug discovery stories of different blockbuster drugs
- Includes the newly approved drugs
- Covers key aspects related to the drug development of the drugs
Preț: 1012.97 lei
Preț vechi: 1255.73 lei
-19% Nou
Puncte Express: 1519
Preț estimativ în valută:
193.83€ • 202.92$ • 160.38£
193.83€ • 202.92$ • 160.38£
Carte tipărită la comandă
Livrare economică 29 martie-12 aprilie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780443239328
ISBN-10: 0443239320
Pagini: 710
Dimensiuni: 216 x 276 mm
Greutate: 1.84 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0443239320
Pagini: 710
Dimensiuni: 216 x 276 mm
Greutate: 1.84 kg
Editura: ELSEVIER SCIENCE
Cuprins
Section 1: Drug discovery techniques and Strategies
1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery
2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application
3. Hit Discovery from DNA-Encoded Chemical Libraries
4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy
5. Macrocyclization strategy in kinase drug discovery
6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules
7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments
8. A future battle, small molecule drugs for cancer stem cell targeted therapy
9. Stem cell therapies for combating emerging and re-emerging viral infections
10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases
11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?
12. Selenium and small molecules: a symbiotic partnership
13. Novel Combinations of CD33-Targeted Immunotherapies
14. Novel payloads of antibody–drug conjugates
15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines
16. mRNA Vaccines: The Next Frontier in Disease Prevention
17. Unravelling the drying techniques of protein biopharmaceuticals
Section 2: Drug discovery case studies
18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections
19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-19
20. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer
21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer
22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer
23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community
24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia
25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor
27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure
29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis
30. Oliceridine (TRV-130): A Biased Agonist of the μ Opioid Receptor as a Novel Analgesic
31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis
32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin
33. Antidiabetic Drugs Targeted PPARγ: From Full Agonists to Selective Modulators
34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis
35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease
1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery
2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application
3. Hit Discovery from DNA-Encoded Chemical Libraries
4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy
5. Macrocyclization strategy in kinase drug discovery
6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules
7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments
8. A future battle, small molecule drugs for cancer stem cell targeted therapy
9. Stem cell therapies for combating emerging and re-emerging viral infections
10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases
11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?
12. Selenium and small molecules: a symbiotic partnership
13. Novel Combinations of CD33-Targeted Immunotherapies
14. Novel payloads of antibody–drug conjugates
15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines
16. mRNA Vaccines: The Next Frontier in Disease Prevention
17. Unravelling the drying techniques of protein biopharmaceuticals
Section 2: Drug discovery case studies
18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections
19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-19
20. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer
21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer
22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer
23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community
24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia
25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor
27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure
29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis
30. Oliceridine (TRV-130): A Biased Agonist of the μ Opioid Receptor as a Novel Analgesic
31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis
32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin
33. Antidiabetic Drugs Targeted PPARγ: From Full Agonists to Selective Modulators
34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis
35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease